Temozolomide Salvage Chemotherapy for Recurrent Anaplastic Oligodendroglioma and Oligo-AstrocytomaTemozolomide Salvage Chemotherapy for Recurrent Anaplastic Oligodendroglioma and Oligo-Astrocytoma
- Other Titles
- Temozolomide Salvage Chemotherapy for Recurrent Anaplastic Oligodendroglioma and Oligo-Astrocytoma
- Authors
- 곽호신; 이기택; 박철기; 김진욱; 홍용길; 강석구; 김정훈; 설호준; 정태영; 장종희; 유헌; 황정현; 김세혁; 박봉진; 황선철; 김민수; 김선환; 김은영; Ealmaan Kim; 김해유; 고영초; 윤환중; 윤지혜; 김주영; 이병길; 이승훈
- Issue Date
- 2013
- Publisher
- 대한신경외과학회
- Keywords
- Anaplastic oligodendroglioma · Anaplastic oligoastrocytoma · Chemotherapy · Recurrence · Temozolomide.
- Citation
- Journal of Korean Neurosurgical Society, v.54, no.6, pp 489 - 498
- Pages
- 10
- Journal Title
- Journal of Korean Neurosurgical Society
- Volume
- 54
- Number
- 6
- Start Page
- 489
- End Page
- 498
- URI
- https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/14130
- ISSN
- 2005-3711
1598-7876
- Abstract
- Objective : To evaluate the efficacy of temozolomide (TMZ) chemotherapy for recurrent anaplastic oligodendroglioma (AO) and anaplastic oligoastrocytoma (AOA).
Methods : A multi-center retrospective trial enrolled seventy-two patients with histologically proven AO/AOA who underwent TMZ chemotherapy for their recurrent tumors from 2006 to 2010. TMZ was administered orally (150 to 200 mg/m2/day) for 5 days per 28 days until unacceptable toxicity occurred or tumor progression was observed.
Results : TMZ chemotherapy cycles administered was median 5.3 (range, 1-41). The objective response rate was 24% including 8 cases (11%) of complete response and another 23 patients (32%) were remained as stable disease. Severe side effects (≥grade 3) occurred only in 9 patients (13%). Progression-free survival (PFS) of all patients was a median 8.0 months (95% confidence interval, 6.0-10.0). The time to recurrence of a year or after was a favorable prognostic factor for PFS (p<0.05). Overall survival (OS) was apparently differed by the patient’s histology, as AOA patients survived a median OS of 18.0 months while AO patients did not reach median OS at median follow-up of 11.5 months (range 2.7-65 months). Good performance status of Eastern Cooperative Oncology Group 0 and 1 showed prolonged OS (p<0.01).
Conclusion : For recurrent AO/AOA after surgery followed by radiation therapy, TMZ could be recommended as a salvage therapy at the estimated efficacy equal to procarbazine, lomustine, and vincristine (PCV) chemotherapy at first relapse. For patients previously treated with PCV, TMZ is a favorable therapeutic option as 2nd line salvage chemotherapy with an acceptable toxicity rate.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Neurosurgery > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/14130)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.